{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:08:14Z","timestamp":1774386494114,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T00:00:00Z","timestamp":1323734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T00:00:00Z","timestamp":1323734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/leu.2011.355","type":"journal-article","created":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T09:58:21Z","timestamp":1323770301000},"page":"959-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase"],"prefix":"10.1038","volume":"26","author":[{"given":"F J","family":"Giles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P D","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Blakesley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N J","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S L","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,13]]},"reference":[{"key":"BFleu2011355_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.hoc.2004.03.005","volume":"18","author":"FJ Giles","year":"2004","unstructured":"Giles FJ, Cortes JE, Kantarjian HM, O\u2019Brien SM . Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 753\u2013774.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 1","key":"BFleu2011355_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","volume":"35","author":"FJ Giles","year":"2008","unstructured":"Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T et al. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 2008; 35 (Suppl 1): S1\u2013S17.","journal-title":"Semin Oncol"},{"key":"BFleu2011355_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9343(93)90122-6","volume":"94","author":"PM Derderian","year":"1993","unstructured":"Derderian PM, Kantarjian HM, Talpaz M, O\u2019Brien S, Cork A, Estey E et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94: 69\u201374.","journal-title":"Am J Med"},{"key":"BFleu2011355_CR4","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","volume":"14","author":"M Hazarika","year":"2008","unstructured":"Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C et al. Tasigna for chronic and accelerated phase Philadelphia chromosome\u2014positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14: 5325\u20135331.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011355_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1586\/ehm.10.61","volume":"3","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol 2010; 3: 665\u2013673.","journal-title":"Expert Rev Hematol"},{"key":"BFleu2011355_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2011355_CR7","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542\u20132551.","journal-title":"N Engl J Med"},{"key":"BFleu2011355_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"BFleu2011355_CR9","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1053\/j.seminhematol.2009.01.011","volume":"46","author":"FJ Giles","year":"2009","unstructured":"Giles FJ . New directions in the treatment of imatinib failure and\/or resistance. Semin Hematol 2009; 46 (Suppl 3): S27\u2013S33.","journal-title":"Semin Hematol"},{"key":"BFleu2011355_CR10","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood.V99.7.2304","volume":"99","author":"J Wadhwa","year":"2002","unstructured":"Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304\u20132309.","journal-title":"Blood"},{"key":"BFleu2011355_CR11","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794\u20132799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2011355_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254\u20132264.","journal-title":"J Clin Invest"},{"key":"BFleu2011355_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557\u2013560.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","volume":"22","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Heim D . Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 431\u2013443.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2011355_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834\u20131839.","journal-title":"Blood"},{"key":"BFleu2011355_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010; 24: 1299\u20131301.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR17","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540\u20133546.","journal-title":"Blood"},{"key":"BFleu2011355_CR18","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207\u20133213.","journal-title":"Blood"},{"key":"BFleu2011355_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.leu.2404137","volume":"20","author":"JS Khorashad","year":"2006","unstructured":"Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 658\u2013663.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1517\/17425255.2011.562892","volume":"7","author":"A Brozik","year":"2011","unstructured":"Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011; 7: 623\u2013642.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFleu2011355_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/187231210791292726","volume":"4","author":"A Haouala","year":"2010","unstructured":"Haouala A, Rumpold H, Untergasser G, Buclin T, Ris HB, Widmer N et al. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett 2010; 4: 114\u2013119.","journal-title":"Drug Metab Lett"},{"key":"BFleu2011355_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010; 38: 1371\u20131380.","journal-title":"Drug Metab Dispos"},{"key":"BFleu2011355_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL . Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010; 24: 765\u2013770.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2009.242","volume":"24","author":"DK Hiwase","year":"2010","unstructured":"Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP . Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010; 24: 658\u2013660.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR25","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176\u20132183.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1517\/13543784.17.6.865","volume":"17","author":"T O\u2019Hare","year":"2008","unstructured":"O\u2019Hare T, Eide CA, Deininger MW . New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008; 17: 865\u2013878.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFleu2011355_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-9966-30-8","volume":"30","author":"B Long","year":"2011","unstructured":"Long B, Zhu H, Zhu C, Liu T, Meng W . Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. J Exp Clin Cancer Res 2011; 30: 8.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFleu2011355_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2011.7","volume":"25","author":"LF Peterson","year":"2011","unstructured":"Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia 2011; 25: 761\u2013769.","journal-title":"Leukemia"},{"key":"BFleu2011355_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500\u2013502.","journal-title":"Blood"},{"key":"BFleu2011355_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bcp.2009.10.009","volume":"79","author":"NJ Donato","year":"2010","unstructured":"Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M . Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol 2010; 79: 688\u2013697.","journal-title":"Biochem Pharmacol"},{"key":"BFleu2011355_CR31","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/j.1582-4934.2010.01218.x","volume":"15","author":"KR Kelly","year":"2011","unstructured":"Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011; 15: 2057\u20132070.","journal-title":"J Cell Mol Med"},{"key":"BFleu2011355_CR32","first-page":"201","volume":"2","author":"JS Carew","year":"2008","unstructured":"Carew JS, Nawrocki ST, Giles FJ, Cleveland JL . Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2008; 2: 201\u2013204.","journal-title":"Biologics"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011355","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:39:54Z","timestamp":1648737594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,13]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFleu2011355"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.355","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,13]]},"assertion":[{"value":"4 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FJG, MB, F-XM, SLG, RAL, AH and OGO acted as a consultant for and received research funding and honoraria from Novartis; HMK acted as a consultant for and received research funding from Novartis; PD.LeC received research funding and honoraria from Novartis; REB, NJG and KG are employees of Novartis Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}